Contract Research & Services
Contract Research

Contract Research News

View news from other Pharmaceutical sectors:
91-105 of 2114 results
GSK, Adaptimmune Therapeutics expand cancer immunotherapy alliance
By PBR Staff Writer
Pharmaceutical firms GlaxoSmithKline (GSK) and Adaptimmune Therapeutics have expanded their immunotherapy collaboration.
Contract Research & Services > Contract Research > News
Sanofi plans to increase presence in Iran
By PBR Staff Writer
Sanofi has signed a Memorandum of Cooperation (MoC) with the Government of Iran intended at increasing its presence in the country.
Contract Research & Services > Contract Research > News
UK universities, global pharma firms launch therapeutics research fund
By PBR Staff Writer
A consortium of pharmaceutical firms and UK universities has launched a new £40m fund for early drug research.
Contract Research & Services > Contract Research > News
Dynavax, AstraZeneca amend existing deal for asthma drug candidate
Dynavax Technologies and AstraZeneca have signed an amendment to their existing Research Collaboration and License Agreement under which, based on the strategic priorities of the two companies, AstraZeneca will now conduct a Phase 2a safety and efficacy trial of AZD1419 in asthma patients that was originally to be conducted by Dynavax.
Contract Research & Services > Contract Research > News
Hepatocellular carcinoma treatment market will rise to $550m by 2024, report says
The market for the treatment of hepatocellular carcinoma is expected to experience very modest expansion, rising from $420m in 2014 to $550m by 2024, representing a Compound Annual Growth Rate (CAGR) of 2.72%, says research and consulting firm GlobalData.
Contract Research & Services > Contract Research > News
Boehringer Ingelheim, Arena Pharmaceuticals partner to advance research in schizophrenia
Boehringer Ingelheim and Arena Pharmaceuticals have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an undisclosed G protein-coupled receptor (GPCR), which belongs to the group of orphan CNS receptors.
Contract Research & Services > Contract Research > News
Sanofi, Warp Drive Bio expand cancer drug research collaboration
Sanofi and Warp Drive Bio have expanded their existing collaboration in cancer drug research.
Contract Research & Services > Contract Research > News
AstraZeneca collaborates with Moderna, Incyte for new cancer treatments
By PBR Staff Writer
AstraZeneca has signed collaborations with Moderna Therapeutics and Incyte to develop new cancer treatments.
Contract Research & Services > Contract Research > News
Pfizer invests $46m into four early-stage research companies
By PBR Staff Writer
Pfizer has infused $46m into four early-stage research companies working on Conditionally Active Biologics (CABs), immuno-oncology, neurodegenerative technologies and gene therapy.
Contract Research & Services > Contract Research > News
PPD to support Moderna in clinical development of mRNA therapeutics
By PBR Staff Writer
Moderna Therapeutics has selected Pharmaceutical Product Development (PPD) as its clinical development partner for messenger RNA (mRNA) based drug development projects.
Contract Research & Services > Contract Research > News
Peregrine, NCCN partner to evaluate novel cancer treatment combinations with bavituximab
Peregrine Pharmaceuticals has announced a new research collaboration with the National Comprehensive Cancer Network (NCCN) to expand the company's ongoing clinical research and development of bavituximab for the treatment of a range of tumors.
Contract Research & Services > Contract Research > News
Baxalta, Symphogen form immuno-oncology collaboration
By PBR Staff Writer
US biopharmaceutical firm Baxalta has signed an agreement worth up to $1.6bn with Danish biotechnology company Symphogen to develop cancer drugs.
Contract Research & Services > Contract Research > News
Merck, Pfizer and Syndax to investigate avelumab and entinostat combination for ovarian cancer
By PBR Staff Writer
Merck and Pfizer have agreed to partner with Syndax Pharmaceuticals to evaluate a therapy to treat ovarian cancer.
Contract Research & Services > Contract Research > News
Lixte licenses LB-100 anti-cancer compound to Taipei Medical University
By PBR Staff Writer
Lixte Biotechnology has granted an exclusive license of its lead anti-cancer compound, LB-100, to Taipei Medical University (TMU).
Contract Research & Services > Contract Research > News
Bayer, CRISPR to create JV to develop new gene therapies
By PBR Staff Writer
Bayer and CRISPR Therapeutics have agreed to establish a joint venture (JV) to develop new treatments for curing blood disorders, blindness and congenital heart disease.
Contract Research & Services > Contract Research > News
91-105 of 2114 results